Occult epidermal growth factor receptor-mutant lung adenocarcinoma complicated by prostatic metastasis: a case report [0.03%]
伴前列腺转移的隐匿性表皮生长因子受体突变型肺腺癌一例报告
Fan Yang,Xing Zhao,Hua Xie et al.
Fan Yang et al.
Herein, we report a case of occult epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma complicated by prostatic metastasis. A 75-year-old male with >30 years of smoking history presented with lower back pain as the initial sy...
Low-dose anlotinib plus immune checkpoint inhibitors offers better efficacy and safety in advanced non-small cell lung cancer treatment [0.03%]
小剂量安罗替尼联合免疫检查点抑制剂在晚期非小细胞肺癌治疗中具有更好的疗效和安全性
Tingfei Tan,Siyu Yuan,Weiwei Chu et al.
Tingfei Tan et al.
The combination of anlotinib with immune checkpoint inhibitors (ICIs) has become a common treatment modality in clinical practice. However, the optimal dose of anlotinib to use remains unclear. We collected patients with advanced non-small ...
Effect of adjuvant chemotherapy with toad venom injection in the treatment of intermediate and advanced colon cancer and its effect on cellular immunity, PTEN, and PI3k [0.03%]
蟾毒类注射液辅助化疗对中晚期结肠癌患者细胞免疫功能及PTEN、PI3K的影响
Haijun Ding,Xuedian Tang,Wenjun Tang
Haijun Ding
The objective of this study is to explore the effect of adjuvant chemotherapy with toad venom injection in patients with intermediate and advanced colon cancer, in order to provide new reference drugs for clinical treatment. Prospectively, ...
Transformation from acquired EGFR 19del/C797S to EGFR 19del/T790M in an advanced non-small cell lung cancer patient: a case report and literature review [0.03%]
晚期非小细胞肺癌患者EGFR 19外显子缺失/C797S转换为EGFR 19外显子缺失/T790M的转变：一例病例报道及文献复习
Xianhuai Jin,Yaping Quan,Jiao Liu et al.
Xianhuai Jin et al.
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the first-line treatment of choice for patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC). However, patients treated with these ...
The tetravalent, bispecific properties of FS118, an anti-LAG-3/PD-L1 antibody, mediate LAG-3 shedding from CD4+ and CD8+ tumor-infiltrating lymphocytes [0.03%]
抗LAG-3/PD-L1抗体FS118的四价，双特异性属性介导CD4 +和CD8 +肿瘤浸润淋巴细胞中的LAG-3脱落
Claire S Reader,Wenjia Liao,Beatrice J Potter-Landua et al.
Claire S Reader et al.
Tumor-infiltrating lymphocytes (TILs) often have upregulated expression of immune checkpoint receptors, such as programmed cell death 1 (PD-1) and lymphocyte-activation gene 3 (LAG-3). Patients treated with antibodies targeting PD-1 or its ...
Iruplinalkib for G1202R-mutant non-small cell lung cancer with anaplastic lymphoma kinase double fusion failed to alectinib: a case report [0.03%]
伊鲁普林拉克伊布治疗ALK双融合突变G1202R非小细胞肺癌失败一例报告：对阿来替尼耐药的病例报告
Guangjian Yang,Jiaqi Hu,Runze Liu et al.
Guangjian Yang et al.
The novel and highly selective anaplastic lymphoma kinase (ALK) inhibitor iruplinalkib showed potent activity and manageable safety profiles in patients with ALK-rearranged non-small cell lung cancer (NSCLC). However, the evidence of irupli...
FSP1 expression as a predictor of platinum resistance and recurrence in epithelial ovarian cancer [0.03%]
FSP1表达作为预测上皮性卵巢癌铂类药物耐药和复发的标志物
Hang Xing,Hai-Ning Bi,Qi Yin et al.
Hang Xing et al.
The objective of this study is to assess the differential expression of ferroptosis suppressor protein 1 (FSP1) in relation to clinical features, platinum resistance, and recurrence in epithelial ovarian cancer (EOC). In addition, the poten...
Combined protein and transcriptomics identifies DCTPP1 as a putative biomarkers for predicting immunotherapy responsiveness in gastric cancer patients [0.03%]
结合蛋白质组学和转录组学鉴定DCTPP1作为预测胃癌患者免疫治疗反应性的潜在生物标志物
Jun Wei,Yuexuan Qin,Luwen Zhang et al.
Jun Wei et al.
This study aimed to screen the changes after overexpression of dCTP pyrophosphatase 1 (DCTPP1) in human gastric adenocarcinoma cells (AGS) cells by proteome and transcriptome sequencing. Gene Ontology and Kyoto Encyclopedia of Genes and Gen...
Long-term survival of an ALK fusion lung adenocarcinoma patient with high mutation burden and microsatellite instability high: a case report [0.03%]
携带ALK融合基因的高突变负荷和微卫星高度不稳定肺腺癌长期幸存者的病例报告
Yanrong Guo,Jinfang Zhai,Yanli Yang et al.
Yanrong Guo et al.
Immune checkpoint blockage (ICB) therapy has shown minimal effectiveness in anaplastic lymphoma kinase (ALK)-positive nonsmall cell lung cancer (NSCLC) regardless of Programmed death-ligand 1 expression. ALK fusion accompanied by mismatch r...
Clinical efficacy and safety of sintilimab plus oral vinorelbine as first-line treatment for newly diagnosed stage IIIB-IV nonsmall cell lung cancer patients with performance status 2 or age ≥75 years [0.03%]
特瑞普利单抗联合口服长春瑞滨治疗PS=2或年龄≥75岁的初治ⅢB～Ⅳ期非小细胞肺癌患者的一项临床研究
Wenzhong Su,Jianqiang Li
Wenzhong Su
This study aimed to evaluate the efficacy and safety of sintilimab combined with oral vinorelbine in newly diagnosed patients with stage IIIb to IV nonsmall cell lung cancer (NSCLC) who had an Eastern Cooperative Oncology Group performance ...